Xtandi May Work Better With TET
Androgen deprivation therapy (ADT) is a first line treatment for men when prostate cancer has spread beyond the prostate. Men die from prostate cancer after their disease becomes castration resistant prostate cancer (CRPC). Anti-androgen treatments [...]
Quality of Life Improvements Help Extend Life While On Xofigo
You may live longer if you feel good about life while taking radium-223 (Xofigo). Dr Neal Shore from the Carolina Urologic Research Center studied how health related quality of life (HRQoL) might be related to [...]
Testosterone Levels May Predict Hormone Treatment Effectiveness
Advanced prostate cancer patients who started androgen deprivation treatment (ADT) treatment with low testosterone levels had worse 1-year progression-free and overall survival after continuous ADT than men with higher testosterone levels. This means that men [...]
Urologists Fail to Complete Psycho-Social and Sexual Histories of Prostate Cancer Patients
Malecare and the University of Minnesota collaborated on the first study to investigate what gay and bisexual men are offered and what they try as rehabilitation to address the sexual and urinary effects of prostate cancer [...]
Biopsy Slides Can Now Be Digitalized and Reviewed by Pathologists
The first whole slide imaging (WSI) system that allows for review and interpretation of digital prostate cancer pathology slides prepared from biopsied tissue has been approved by the U.S. Food and Drug Administration (FDA). Malecare is [...]
Blood Test Determines Effectiveness of Zytiga and or Xtandi, Before You Begin Treatment.
Adna is a new blood test that will tell you if Zytiga and Xtandi will or will not treat castration resistant prostate cancer. Imagine knowing if Zytiga and or Xtandi will fail to help you, [...]